
|Articles|July 1, 2003
Overview of Efalizumab Patient-reported Outcomes Trials
After treatment with the new biologic agents, patient-reported outcomes measuring quality of life were evaluated, since psoriasis has been shown to have a significantly negative impact on patients' physical, psychological, and social functioning.22 Because the condition can affect the ability to perform normal work activities and often causes absence from work, psoriasis can negatively affect a person's job and income.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
2
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
3
Clinicians Weigh Topical Sequencing and Escalation in Complex Atopic Dermatitis Cases
4
Biologic Therapies in AD and CSU: Progress and the Push for Precision Medicine
5











